Gilead licenses respiratory, herpes antiviral research programs from Novartis
The antivirus programs include investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.
Read More
Tag: rhinovirus
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
